Compare JELD & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JELD | MDXH |
|---|---|---|
| Founded | 1960 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Forest Products | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.8M | 183.4M |
| IPO Year | 2016 | 2021 |
| Metric | JELD | MDXH |
|---|---|---|
| Price | $1.54 | $3.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.43 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 1.6M | 110.0K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | $30.31 |
| Revenue Next Year | $2.31 | $18.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.51 | $1.36 |
| 52 Week High | $6.98 | $5.33 |
| Indicator | JELD | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 26.92 | 42.88 |
| Support Level | N/A | $3.05 |
| Resistance Level | $2.06 | $3.78 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 4.71 | 15.09 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.